专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060148750A1 Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol 审中-公开
标题翻译：表达密码子优化的HIV-1 Pol和修饰的HIV-1 Pol的多核苷酸疫苗
公开(公告)号：US20060148750A1
公开(公告)日：2006-07-06
申请号：US11345127
申请日：2006-02-01
申请人： John Shiver , Helen Perry , Danilo Casimiro , Tong-Ming Fu
发明人： John Shiver , Helen Perry , Danilo Casimiro , Tong-Ming Fu
IPC分类号： A61K48/00
CPC分类号： C07K14/005 , A61K2039/53 , C07H21/02 , C12N2740/16222 , C12N2740/16234 , C12N2800/22
摘要： Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, reverse transcriptase activity, RNase H activity and integrase activity, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins which comprise an amino terminal leader peptide.
摘要翻译：公开了包含HIV Pol DNA疫苗的药物组合物以及这些DNA疫苗的生产和使用。将本发明的基于pol的DNA疫苗直接施用于活的脊椎动物组织，优选人，并且优选表达不含蛋白酶的HIV Pol蛋白，逆转录酶活性，RNase H活性和整合酶活性的失活形式，诱导细胞免疫具体承认人体免疫缺陷病毒-1（HIV-1）的反应。构成这些DNA疫苗的开放阅读框架的DNA分子是编码经优化的HIV-1 Pol的密码子优化的HIV-1 Pol和密码子优化的非活性衍生物的合成DNA分子，其包括编码无效Pol蛋白的DNA分子，其包含氨基末端引物肽。

2. 发明申请

US20050106123A1 Method of inducing an enhanced immune response against hiv 审中-公开
标题翻译：诱导针对HIV的增强的免疫应答的方法
公开(公告)号：US20050106123A1
公开(公告)日：2005-05-19
申请号：US10507098
申请日：2003-03-12
申请人： Emilio Emini , John Shiver , Michael Chastain , Danilo Casimiro , Tong-Ming Fu , Xiaoping Liang
发明人： Emilio Emini , John Shiver , Michael Chastain , Danilo Casimiro , Tong-Ming Fu , Xiaoping Liang
IPC分类号： A61K39/00 , A61K39/21 , C07K14/16 , C12N15/861 , C12N15/863 , A61K48/00 , A61K39/12 , C12N15/867
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/545 , C07K14/005 , C12N2710/10343 , C12N2710/24043 , C12N2710/24143 , C12N2740/15034 , C12N2740/16122 , C12N2740/16134 , C12N2740/16234 , C12N2830/42
摘要： An efficient means of inducing an immune response against human immunodeficiency virus (“HIV”) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol wherein recombinant adenoviral and poxvirus vectors comprising exogenous genetic material encoding a common HIV antigen are administered in that order. Vaccines administered into living vertebrate tissue in accordance with the disclosed regimes, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 antigen (e.g., Gag), inducing a cellular immune response which specifically recognizes HIV-1. It is believed that the disclosed prime/boost regime will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：公开了一种利用特定初始 - 加强方式诱导针对人类免疫缺陷病毒（“HIV”）的免疫应答的有效手段。特异性初始 - 加强方案采用异源初始 - 加强方案，其中包含编码常见HIV抗原的外源遗传物质的重组腺病毒和痘病毒载体以该顺序施用。根据所公开的方案，优选哺乳动物宿主例如商业或家庭兽医重要的人或非人哺乳动物施用于活的脊椎动物组织的疫苗表达HIV-1抗原（例如，Gag），诱导细胞免疫专门承认艾滋病毒1的反应。相信所公开的主要/加强方案将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

3. 发明申请

US20060165664A1 Method of inducing an enhanced immune response against hiv 审中-公开
标题翻译：诱导针对HIV的增强的免疫应答的方法
公开(公告)号：US20060165664A1
公开(公告)日：2006-07-27
申请号：US10507237
申请日：2003-03-12
申请人： Emilio Emini , John Shiver , Danilo Casimiro , Andrew Bett , Xiaoping Liang , Tong-Ming Fu
发明人： Emilio Emini , John Shiver , Danilo Casimiro , Andrew Bett , Xiaoping Liang , Tong-Ming Fu
IPC分类号： A61K48/00 , A61K39/21
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/545 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： An efficient means of inducing an immune response against human immunodeficiency virus (HIV) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol employing recombinant adenoviral vectors of alternative and distinct serotypes comprising exogenous genetic material encoding a common HIV antigen. Vaccines administered into living vertebrate tissue in accordance with the disclosed regimes, preferably a mammalian host, such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 antigen (e.g., Gag), inducing a cellular immune response which specifically recognizes HIV-1. It is believed that the disclosed prime/boost regime will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：公开了一种利用特定初始 - 加强方案诱导针对人类免疫缺陷病毒（HIV）的免疫应答的有效手段。特定的初始 - 加强方案采用异源初始 - 加强方案，其使用包含编码常见HIV抗原的外源遗传物质的替代和不同血清型的重组腺病毒载体。根据所公开的方案，优选哺乳动物宿主，如商业或家畜兽医学重要的人或非人哺乳动物施用于活的脊椎动物组织中的疫苗表达HIV-1抗原（例如，Gag），诱导细胞特异性识别HIV-1的免疫反应。相信所公开的主要/加强方案将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

4. 发明申请

US20150307850A1 CONDITIONAL REPLICATING VIRAL VECTORS 审中-公开
标题翻译：条件替代的VIRAL VECTORS
公开(公告)号：US20150307850A1
公开(公告)日：2015-10-29
申请号：US14649669
申请日：2013-12-04
申请人： Tong-ming FU , Dai WANG , Danilo CASIMIRO , Daniel FREED , Fengsheng LI , MERCK SHARP & DOHME CORP.
发明人： Tong-Ming Fu , Dai Wang , Danilo Casimiro , Daniel C. Freed , Fengsheng Li
IPC分类号： C12N7/00 , A61K39/245 , C07K14/005
CPC分类号： C12N7/00 , A61K39/12 , A61K39/21 , A61K39/245 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2710/16121 , C12N2710/16122 , C12N2710/16134 , C12N2710/16141 , C12N2710/16152 , C12N2710/16162 , C12N2740/16234
摘要： The present invention relates to a cytomegalovirus (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral replication. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are replication defective, or chemically controllable replication capable, or replication competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. Compositions comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention.
摘要翻译：本发明涉及重组改变以表达异源多肽并允许外部控制病毒复制的巨细胞病毒（CMV）。异源多肽可以是感兴趣的多肽，例如抗原，抗体或免疫调节剂。本发明的CMV载体是复制缺陷的，或具有化学上可控的复制能力或复制能力的。本发明还涉及CMV载体的用途，例如在体内诱导对抗原的免疫应答或表达抗体或免疫调节剂。包含表达异源多肽的CMV的组合物也包括在本发明中。

5. 发明申请

US20070054395A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20070054395A1
公开(公告)日：2007-03-08
申请号：US11599584
申请日：2006-11-13
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C12Q1/68 , C12N15/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N15/63 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

6. 发明申请

US20060216272A1 Therapeutic immunization of hiv-infected individuals 审中-公开
标题翻译： HIV感染者的治疗免疫
公开(公告)号：US20060216272A1
公开(公告)日：2006-09-28
申请号：US10571651
申请日：2004-09-14
申请人： Emilio Emini , John Shiver , Danilo Casimiro , Daria Hazuda , William Scheilf
发明人： Emilio Emini , John Shiver , Danilo Casimiro , Daria Hazuda , William Scheilf
IPC分类号： A61K48/00
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/53 , A61K2039/545 , A61K2039/55 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10343 , C12N2740/15022 , C12N2740/15034 , C12N2740/15071 , C12N2740/16134 , C12N2740/16222
摘要： The present invention provides an improved method for eliciting a therapeutic immune response in an individual infected with human immunodeficiency virus (“HIV”). The method comprises administering an adenoviral vaccine composition expressing an HIV antigen to an individual with controlled viremia. Immunization of infected individuals in this manner elicits a cellular-mediated immune response against the virus that is significant both in the level of the response and the breadth of the response. The therapeutic immune response that ensues is capable of effectively maintaining low titers of virus and, thus, offers the prospect of reducing individual dependency on antiviral therapy.
摘要翻译：本发明提供了在感染人类免疫缺陷病毒（“HIV”）的个体中引发治疗性免疫应答的改进方法。该方法包括向具有受控制的病毒血症的个体施用表达HIV抗原的腺病毒疫苗组合物。以这种方式免疫感染的个体引起针对病毒的细胞介导的免疫应答，其在反应水平和反应的广度方面是显着的。随后的治疗性免疫应答能够有效地维持低滴度的病毒，从而提供减少个体对抗病毒治疗依赖性的前景。

7. 发明申请

US20050070017A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20050070017A1
公开(公告)日：2005-03-31
申请号：US10636730
申请日：2003-08-07
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C07K14/16 , C12N7/01 , C12N7/02 , C12N15/861 , A61K39/12 , C12N7/00
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

8. 发明申请

US20070077257A1 Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：增强的第一代腺病毒疫苗表达宽带优化的HIV1-Gag，Pol，Nef和修饰
公开(公告)号：US20070077257A1
公开(公告)日：2007-04-05
申请号：US11604553
申请日：2006-11-27
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： A61K39/00 , A61K39/12
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2710/10351 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：描述了含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的第一代腺病毒载体和基于重组腺病毒的HIV疫苗及其生物学相关的修饰。当直接引入活的脊椎动物组织中时，腺病毒疫苗表达相关蛋白质，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag，HIV-1 Pol，HIV-1 Nef的合成DNA分子及其衍生物。本发明的单独或组合的腺病毒疫苗将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

9. 发明申请

US20080063656A1 Adenoviral Vector Compositions 审中-公开
标题翻译：腺病毒载体组成
公开(公告)号：US20080063656A1
公开(公告)日：2008-03-13
申请号：US11659671
申请日：2005-08-05
申请人： Emilio Emini , John Shiver , Danilo Casimiro , Andrew Bett
发明人： Emilio Emini , John Shiver , Danilo Casimiro , Andrew Bett
IPC分类号： A61K31/70 , A61K35/00 , A61K39/00 , A61P43/00 , C12N15/00 , C12N7/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K48/00 , A61K48/0083 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2740/16134 , C12N2740/16334
摘要： Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a polypeptide(s) (e.g, a protein or antigen) of interest. Adenoviral infection is quite common in the general population, and a large percentage of people have neutralizing antibodies to the more prevalent adenoviral serotypes. Such pre-existing anti-adenoviral immunity can dampen or possibly abrogate the effectiveness of this virus for the delivery and expression of heterologous proteins or antigens. The method taught herein functions to offset pre-existing immunity through the delivery of the protein or antigen by a cocktail of at least two adenoviral serotypes. Utilizing a composition of at least two adenoviral serotypes in this manner has been found to increase the effectiveness of adenoviral administration. Adenoviral vectors of utility in the elicitation of an immune response against Human Immunodeficiency Virus (“HIV”) are also disclosed.
摘要翻译：申请人在此公开了新颖的方法，载体和载体组合物，用于提高编码感兴趣的多肽（例如，蛋白质或抗原）的异源核酸的递送和表达中腺病毒载体的效率。腺病毒感染在普通人群中相当普遍，并且大部分人群对更普遍的腺病毒血清型具有中和抗体。这种预先存在的抗腺病毒免疫可以抑制或可能地消除该病毒用于递送和表达异源蛋白质或抗原的有效性。本文教导的方法通过至少两种腺病毒血清型的混合物通过递送蛋白质或抗原来抵消预先存在的免疫力。已经发现以这种方式利用至少两种腺病毒血清型的组合物来增加腺病毒给药的有效性。还公开了针对人类免疫缺陷病毒（“HIV”）免疫应答的效用的腺病毒载体。

10. 发明申请

US20120177684A1 PAPILLOMAVIRUS VACCINE COMPOSITIONS 审中-公开
标题翻译：肉毒杆菌组合物
公开(公告)号：US20120177684A1
公开(公告)日：2012-07-12
申请号：US13423847
申请日：2012-03-19
申请人： Janine T. Bryan , Michelle K. Brownlow , Li Shi , Danilo Casimiro , William L. McClements , Brian K. Meyer , Binghua Hu
发明人： Janine T. Bryan , Michelle K. Brownlow , Li Shi , Danilo Casimiro , William L. McClements , Brian K. Meyer , Binghua Hu
IPC分类号： A61K39/12 , A61P31/20 , A61P37/04
CPC分类号： A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/55577 , A61K2039/70 , C12N7/00 , C12N2710/20023 , C12N2710/20034
摘要： The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.
摘要翻译：本发明涉及包含HPV病毒样颗粒（VLP），所述VLP吸附于铝佐剂的ISMA型佐剂和包含皂角苷，胆固醇和磷脂的ISCOM型佐剂的药物组合物。在优选的实施方案中，铝佐剂包括无定形的羟基磷酸氢铝硫酸盐。本发明的另一方面提供了包含HPV VLP和选自间甲酚，苯酚和苄醇的抗微生物防腐剂的多剂量HPV疫苗制剂。还提供了使用所公开的药物组合物和制剂在人类患者中诱导针对HPV的免疫应答并防止HPV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式